Evidence map›Paper›PMID 42871410›Full record

ReviewPrzeglad menopauzalny = Menopause review2026

Beyond the panacea: addressing the systemic failure in midlife female sexual health.

Mariam Sherif, Panayoti Bachkangi

Abstract readReview
In one paragraph

Review in Przeglad menopauzalny = Menopause review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mariam SherifDepartment of Clinical Medicine, Near East University, Nicosia, Cyprus.
Panayoti BachkangiDepartment of Obstetrics and Gynaecology, Lothan Hospital, Kuwait City, Kuwait.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Menopause is a universal midlife transition that profoundly impacts physical, psychological, and sexual wellbeing. In recent years, clinical and public attention has increasingly focused on post-reproductive health, with hormone replacement therapy and targeted symptom management gaining renewed prominence. While a growing array of evidence-based treatment options now exists to address vasomotor, mood, and sexual health concerns, the rapid expansion of therapeutic availability has introduced new clinical challenges. The democratisation of sexual and menopausal health information, though valuable in reducing stigma, has paradoxically decoupled patient expectations from clinical complexity. This review critically examines how digital marketing, social media amplification, and consumer-driven demand increasingly curate diagnostic conclusions before the clinical encounter begins. We demonstrate that these structural pressures, compounded by time-constrained consultations and cognitive heuristics, foster a culture of therapeutic shortcutting - most notably through the premature escalation to testosterone therapy for hypoactive sexual desire disorder. By synthesising evidence on clinical inertia, commercial determinants of health, and diagnostic attribution bias, we argue that current practice frequently bypasses rigorous biopsychosocial assessment, reducing multifactorial symptoms to simplistic hormonal narratives. We contextualise this trend within the regulatory precedent of the mid-urethral tape controversy, warning that unchecked diagnostic expansion risks triggering a blunt-instrument regulatory overcorrection that would indiscriminately restrict access to evidence-based therapies. Ultimately, we advocate for a deliberate return to ethical, humanistic gatekeeping. Clinicians must reclaim the consultation as a deliberative, evidence-based encounter: treating the patient not as a product of commercial demand, but as a whole person navigating a complex physiological and psychosocial transition.

Indexed as

clinical inertiacommercial determinants of healthhypoactive sexual desire disordermidlife women’s healthregulatory precedenttestosterone therapy

Identifiers

PMID42871410
PMCPMC13659210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.